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R5/PTG is one of the glycogen 
targeting subunits of type 1 protein 
phosphatase (PP1), a master regulator of 
glycogen synthesis. R5/PTG recruits the 
phosphatase to the places where glycogen 
synthesis occurs, allowing the activation 
of glycogen synthase and the inactivation 
of glycogen phosphorylase, thus 
increasing glycogen synthesis and 
decreasing its degradation. In this report, 
we show that the activity of R5/PTG is 
regulated by AMPK. We demonstrate 
that AMPK interacts physically with 
R5/PTG and modifies its basal 
phosphorylation status. We have also 
mapped the major phosphorylation sites 
of R5/PTG by mass spectrometry 
analysis, observing that phosphorylation 
of Ser8 and Ser268 increased upon 
activation of AMPK. We have recently 
described that the activity of R5/PTG is 
downregulated by the laforin-malin 
complex, composed of a dual specificity 
phosphatase (laforin) and an E3-
ubiquitin ligase (malin). We now 
demonstrate that phosphorylation of 
R5/PTG at Ser8 by AMPK accelerates its 
laforin/malin-dependent ubiquitination 
and subsequent proteasomal 
degradation, which results in a decrease 
of its glycogenic activity. Thus, our 




 Glycogen homeostasis depends 
mainly on the activity of the enzymes 
involved in its synthesis (glycogen 
synthase; GS), and its degradation 
(glycogen phosphorylase; Ph). These 
activities are regulated by a complex 
mechanism involving both allosteric 
regulation and phosphorylation [(1), (2)]. 
Interestingly, while there are several 
kinases (AMPK, PKA, CKI, GSK3) that 
inhibit glycogen synthesis through the 
phosphorylation of GS, there is only one 
known phosphatase (type 1 protein 
phosphatase; PP1) that dephosphorylates 
both GS (leading to its activation) and Ph, 
(leading to its inactivation), which results in 
glycogen accumulation [(1), (2)]. PP1 is 
recruited to glycogen by a family of 
glycogen targeting proteins including: GM, 
GL, R5/PTG, R6 and R3E [(3), (4), (5), (6), 
(7)]. The regulation of the activity of the 
holoenzyme formed by the PP1 catalytic 
subunit and one of these glycogen targeting 
subunits is different in each case. The 
glycogenic activity of GM is downregulated 
by its PKA-dependent phosphorylation; 
PKA phosphorylates GM at a site in its PP1 
binding motif which leads to its 
dissociation from PP1. The glycogenic 
activity of the GL-PP1c holoenzyme is 
downregulated by an allosteric mechanism 
involving phosphorylase-a [(8), (9), (10)]. 
Little is known about the regulation of the 
holoenzymes involving R6 or R3E, but in 
the case of R5/PTG, we and others have 
recently described that its glycogenic 
activity is downregulated by the laforin-
malin complex, composed of a dual 
specificity phosphatase (laforin) and an E3-
ubiquitin ligase (malin), which recognizes 
and ubiquitinates R5/PTG and targets it for 
proteasomal-dependent degradation [(11), 
(12), (13)]. 
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 Laforin and malin are two key 
proteins related to Lafora disease (LD, 
OMIM 254780), an autosomal recessive 
neurodegenerative disorder characterized 
by the presence of glycogen-like 
intracellular inclusions named Lafora 
bodies. Although the role of these two 
proteins in cellular physiology is still 
poorly understood, several reports indicate 
that both the enzymatic activity of each 
protein and the physical interaction between 
them are critical parameters for the 
pathogenesis of LD. The fact that one of the 
histological determinants that characterize 
LD is the accumulation of glycogen-like 
intracellular inclusions suggests a direct 
involvement of the laforin-malin complex 
in the regulation of glycogen biosynthesis 
(14). 
 Contrary to mammalian cells, yeast 
glycogen synthesis is stimulated by nutrient 
limitation. However, the activity of yeast 
glycogen synthase (Gsy2) is similarly 
regulated by phosphorylation. The 
dephosphorylation and activation of Gsy2 is 
carried out mainly by the PP1 holoenzyme 
composed by Gac1 (glycogen targeting 
subunit) and the phosphatase catalytic 
subunit Glc7 (15). It has been described 
that the Snf1 kinase [yeast orthologue of 
mammalian AMP-activated protein kinase 
(AMPK), see below] activates the 
Gac1/Glc7 protein phosphatase complex, 
thus facilitating the activation of Gsy2 
under conditions of Snf1 activation [(15), 
(16)]. 
AMPK is a serine/threonine protein 
kinase that acts as a sensor of cellular 
energy status. Once activated, it switches 
on catabolic pathways and switches off 
many ATP-consuming processes (anabolic 
pathways) [see (17), (18), for reviews]. 
AMPK is a heterotrimer of three different 
subunits: ,  and , each of which has 
different isoforms (1, 2, 1, 2, 1, 2, 
3). AMPK is the catalytic subunit of the 
AMPK complex, AMPK is involved in 
AMP binding and AMPK functions as a 
scaffold to assemble  and  subunits, and 
also determines the subcellular localization 
and substrate specificity of the complex 
[(17), (18)]. 
Since the yeast Snf1 orthologue of 
AMPK is involved in the regulation of the 
yeast PP1 holoenzyme involved in 
glycogen synthesis (Gac1/Glc7; see above), 
in this work we studied whether AMPK 
could regulate similar PP1 holoenzymes in 
mammalian cells. We found that AMPK 
interacted physically with the R5/PTG 
glycogen targeting subunit and made it a 
better substrate for its laforin/malin-
dependent degradation, resulting in a 
decrease of its glycogenic activity. 
 
EXPERIMENTAL PROCEDURES 
Cell culture and treatments- 
Chinese hamster ovary (CHO) and human 
embryonic kidney (Hek293) cells were 
grown in Ham’s F-12 medium (GIBCO) or 
DMEM (Lonza) respectively supplemented 
with 100 units/mL penicillin, 100 μg/mL 
streptomycin, 2 mM glutamine, 10% 
inactivated fetal bovine serum (FBS, 
GIBCO). 1.5x106 cells were plated onto 
60mm-diameter culture dishes the day 
before transfection. Cells were transfected 
with 1 μg of each plasmid using 
Lipofectamine 2000 (Invitrogen). When 
indicated, cycloheximide 100 µM was 
added for different periods of time. Twenty-
four hours after transfection, cells were 
scraped on ice in lysis buffer [10 mM 
TrisHCl pH 8; 150 mM NaCl, 15 mM 
EDTA; 0.6 M sucrose, 0.5% nonidet P-40 
(NP-40), complete protease inhibitor 
cocktail (Roche), 1 mM PMSF, 50 mM 
NaF and 5 mM Na2P2O7]. Cells were lysed 
by repeated passage through a 25-gauge 
needle. Twenty-five g of total protein 
from the soluble fraction of cell lysates 
were analyzed by SDS-PAGE and western 
blotting using appropriate antibodies: 
mouse monoclonal anti-laforin (12), rabbit 
polyclonal anti-R5/PTG (raised against the 
synthetic peptide (GPYDEFQRRHFVNK) 
corresponding to amino acids 16-29 of the 
human R5/PTG), mouse monoclonal anti-
HA (Sigma), mouse monoclonal anti-
tubulin (Santacruz Biotech) or rabbit 
polyclonal anti-actin (Sigma) as in (12). 
Human primary skin fibroblasts, either 
from LD patients or healthy subjects (12), 
were cultured in DMEM-15%FBS with the 
antibiotics and glutamine described above. 
Plasmids- To construct plasmid 
pACT2-GM, a BglII fragment containing 
the rabbit GM open reading frame from 
pcDNA3-FLAG-rabGM [(19), a gift from 
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Dr. D.L. Brautigan; Center for Cell 
Signalling, University of Virginia, USA] 
was subcloned into pUC18; then, a 
BamHI/SalI fragment was subcloned into 
pACT2 (20). Plasmid pACT2-GL was 
obtained by subcloning into pACT2 a 
BamHI/SalI fragment of a PCR-amplified 
human GL open reading frame using the 
IMAGE Consortium clone nº 13484-G21 as 
a template. Plasmid pACT2-R5/PTG 
contained the human full length R5/PTG 
ORF (21). Plasmids pACT2-R5/PTG 
(Ser8Ala, Ser8Asp, S268Ala and S268Asp) 
were generated by subcloning the mutated 
R5/PTG fragments (described below), into 
pACT2 vector. A SfiI/BglII fragment from 
pACT2-R5/PTG wild type was subcloned 
into vector pCMV-HA (Clontech) in order 
to obtain plasmid pCMV-HA-R5/PTG. An 
8xHis tag was inserted into pCMV-HA-R5 
by digestion with SfiI/SmaI and religation 
with hybridized primers 5´-
CACATCATCATCATCATCATCATCAT
GC-3´ and 5´- 
GCATGATGATGATGATGATGATGAT
GTGCCA-3´, yielding plasmid pCMV-HA-
8xHis-R5/PTG. To express R5/PTG in 
bacteria, we subcloned an EcoRI/SalI 
fragment containing the R5/PTG ORF into 
plasmid pMALC2 (New England Biolabs), 
which produces an N-terminal fusion of 
R5/PTG with the maltose binding protein. 
Human PP1α was amplified by 
PCR from a human fetal liver cDNA library 
and cloned into BamHI/SalI sites of 
pBTM116, resulting in plasmid pBTM-
PP1α. 
Plasmid pcDNA3-AMPKα2 T172D 
(expressing a constitutively active form of 
AMPK2), pcDNA3-AMPK2 and 
pcDNA3-AMPK γ1 were kindly provided 
by Dr. D. Carling (Cellular Stress Group, 
MRC Clinical Sciences Centre, Imperial 
College School of Medicine, Hammersmith 
Hospital, London). Other plasmids used in 
this study were pBTM-AMPK2, pBTM-
AMPK2, pBTM-AMPK1 and pCMV-




directed mutagenesis of R5/PTG constructs 
was performed using the Quick Change kit 
(Stratagene) and the following primers: a) 

















TGTGCCAAGCAAAGCCTCAT -3'; d) 






3'. Mutations, and construct fidelity were 
confirmed by DNA sequencing. 
Laforin siRNA silencing- The 
mammalian expression vector, 
pSUPER.neo.GFP (Oligoengine) was used 
for expression of laforin-specific siRNA in 
human Hek293 cells. Sense and anti-sense 
oligonucleotides corresponding to 
nucleotides 872-891 of human EPM2A 
cDNA (GenBank accession no. 
NM_005670) were annealed and subcloned 
into pSUPER.neo.GFP vector, resulting in 
plasmid pSUPER-laf. 
Yeast two hybrid analyses- The 
yeast CTY10.5d strain was co-transformed 
with combinations of pACT2-GM, pACT2-
GL and pACT2-R5/PTG and different 
pBTM-AMPK2, pBTM-AMPK2 and 
pBTM-AMPK1 plasmids. To analyze the 
effect of phosphorylation of R5/PTG on its 
protein-protein interactions, plasmid 
pACT2-R5/PTG (wild type or S8A and 
S268A mutants) were co-transformed with 
pBTM-PP1α, pBTM-AMPKα2, pBTM-
AMPKβ2 or pEG202-Laforin. 
Transformants were grown in selective SC 
medium and -galactosidase activity was 
assayed in permeabilized cells and 
expressed in Miller Units as in (23). 
Co-immunoprecipitation analysis- 
Human embryonic kidney cells (Hek293) 
transfected with plasmids pCMV-HA-
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R5/PTG and pCMV-myc-AMPK2 or with 
the corresponding empty plasmids were 
used for co-immunoprecipitation studies 
carried out as in (22). In the case of co-
immunoprecipitation of endogenous 
proteins, crude extracts from mouse skeletal 
muscle (C57B6 mice) were prepared by 
homogenizing the samples with a tissue 
homogenizer in ice-cold lysis buffer 
containing 100 mM KCl, 25mM Tris-
HCl pH 8, 10% glycerol, 0.5% Triton-
X100, 5mM NaF, 5mM Na2P2O7, 1mM 
PMSF, 2mM NaVO4 and protease 
inhibitor cocktail (Roche) and then 
clarified by centrifugation at 5,000 rpm, 
5 min, at 4ºC. One and half mg of total 
protein from the soluble fraction was 
used for immunoprecipitation using 
specific anti-R5/PTG antibody or pre-
immune serum and protein A/G-plus 
agarose (Santacruz Biotech). 
Immunoprecipitates were analyzed by 
western-blotting using polyclonal anti-
AMPK antibody (Cell Signaling 
Technology). 
2D-electrophoresis- CHO cells 
were transfected with the corresponding 
plasmids and 24 hours after transfection, 
extracts were made in urea lysis buffer (9.7 
M urea, 4% CHAPS, 20 mM DTT). HA-
R5/PTG was analyzed by two-dimensional 
electrophoresis (2D-E) using an IPGphor 
(Amersham Bioscience, Uppsala, Sweden) 
instrument. For the first dimension (IEF), 
50 μg of total protein (in 100 μL of 9.7 M 
urea, 4% CHAPS, 20 mM DTT and 0.5 % 
IPG buffer) were loaded on a 7 cm IPG 
strip (pH range 6-11) using the following 
focusing conditions: 500 V for 30 min, 
1000 V for 30 min and 5000 V for 80 min. 
Electrophoretic separation (second 
dimension) was performed in a SDS-
PAGE. 
-phosphatase treatment- CHO cell 
crude extracts (50 g) in -phosphatase 
buffer containing 2 mM MnCl2 were treated 
at 30ºC for 30 min with 50 Units of -
phosphatase (New England Biolabs). The 
reactions were stopped by adding two 
volumes of urea lysis buffer. 
Expression of recombinant MBP-
R5/PTG in E. coli- E.coli transformants 
harboring MBP-R5/PTG fusion were grown 
in 500 ml of LB/ampicillin. Transformants 
were grown at 37ºC until the absorbance at 
600 nm reached a value of around 0.3. 
IPTG (isopropyl--D-thiogalactoside) was 
then added to a concentration of 0.1 mM, 
and cultures were maintained overnight at 
25 ºC. Cells were harvested and 
resuspended in 20 ml of sonication buffer 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
0.2 mM EDTA, 10% glycerol, 0.1% Triton 
X-100, 2 mM DTT, 2 mM PMSF and 
complete protease inhibitor cocktail 
(Roche)]. Cells were disrupted by 
sonication and the fusion protein was 
purified by passing the extracts through 1 
ml bed volume of amylose-sepharose 
columns (Sigma). MBP-fusion proteins 
were eluted from the column with 50 mM 
maltose in a buffer containing 50 mM Tris-
HCl pH 7.5, 150 mM NaCl, and 15% 
glycerol. Samples were stored at -80ºC. 
AMPK in vitro phosphorylation 
assay- 50 ng of purified MBP-R5/PTG 
fusion protein were phosphorylated with 50 
mU of AMPK (Upstate), in a final volume 
of 20 l of a buffer containing 20 mM 
HEPES-NaOH pH 7.0, 1 mM dithiothreitol, 
10 mM MgCl2, 300 M AMP and 100 M 
of a mixture of -32P-ATP (3,000 Ci/mmol) 
and cold ATP, following the 
manufacturer’s instructions (Upstate). The 
reaction was incubated at 30ºC for 1 hr and 
stopped by boiling the mixtures in sample 
buffer. Samples were analyzed by SDS-
PAGE and autoradiography. 250 ng of 
MBP-fusion proteins were analyzed by 
SDS-PAGE and stained with Coomassie 
blue. 
R5/PTG purification and mass 
spectrometry- CHO cells were transfected 
with plasmid pCMV-HA-8xHis-R5/PTG 
using Lipofectamine 2000. Cell lysates 
from 20 plates (100mm-diameter plates) 
were used for purification of poly-His-
tagged R5/PTG. Twenty-four hours after 
transfection, cells were harvested in lysis 
buffer (0.15 M NaCl, 10mM Tris-HCl pH 
7.5, 15mM EDTA pH 8.0, 0.6M sucrose, 
50mM NaF, 5mM Na2P2O7, 1mM PMSF 
and protease inhibitor cocktail). Cell 
extracts were centrifuged at 8000rpm for 
20min at 4ºC. The resulting pellet was 
resuspended in Buffer A (8M urea, 250mM 
NaCl, 100 mM Tris–HCl, pH 7.5, 0.1% 
NP40 ) and then used for purification using 
an FPLC AKTA system and a His-Trap 
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column (GE Healthcare). Additionally, 
poly-His-tagged R5/PTG was purified from 
CHO cells infected with an adenovirus 
expressing a mutated form of AMPK1 
subunit (R70Q) that renders a constitutively 
active AMPK complex. Purified samples 
were analyzed by SDS–PAGE 
electrophoresis and coomassie staining. The 
band corresponding to HA-8xHis-R5/PTG 
was excised and digested in situ with 
trypsin, and the resulting peptides were 
analyzed by MALDI-TOF/MS and HPLC-
MS/MS. Proteomic analysis was performed 
at the Prince Felipe Research Centre (CIPF-
Valencia, a node of the Spanish ProteoRed 
network). MALDI-TOF/MS and HPLC-
MS/MS data were analyzed with the 
bioinformatics data base system Mascot 
(Matrix Sciences, London), and Paragon 
(ProteinPilot™). These data confirmed the 
identity of the purified protein. Ion 
fragmentation analysis assigned S8 and 
S268 as the phosphorylated residues within 
R5/PTG sequence. Comparative analysis of 
HPLC-MS/MS data using Decyder MS 
software showed that S8 and S268 were 
quantitatively more phosphorylated when 
purified in the presence of a constitutively 
active AMPK. 
Glycogen determination- Glycogen 
determination in transfected Hek293 cells 
was carried out as in (24). 
Statistical data analysis- Data are 
expressed as means ± standard deviation 
(SD). Statistical significance of differences 
between the groups was evaluated by a 
paired Student’s t test with two-tailed 
distribution. The significance has been 
considered at * p<0.05, ** p<0.01 and *** 
p<0.001, as indicated in each case. 
 
RESULTS 
1) R5/PTG interacts physically with and 
it is an in vitro target of AMPK. 
 To study the possible functional 
relationship between AMPK and the 
glycogen targeting subunits of PP1, we 
analyzed, in a yeast two-hybrid system, the 
interaction between the different AMPK 
subunits and the PP1 glycogen targeting 
subunits GM (PPP1R3), GL (PPP1R4) and 
R5/PTG (PPP1R5) [(1), (8)]. In the assays, 
we used the catalytic AMPK2 subunit, the 
scaffolding AMPK2 subunit and the 
regulatory AMPK1 subunit, since they are 
abundant in glycogenic tissues, such as 
liver and skeletal muscle [(25), (26)]. As 
shown in Fig. 1A, we only detected a robust 
two-hybrid interaction between both the 2 
catalytic and 2 regulatory subunits of the 
AMPK complex and the R5/PTG glycogen 
targeting subunit. AMPK2 could also 
interact with GL, although to a lesser extent. 
To confirm the interaction between AMPK 
subunits and R5/PTG, we expressed a myc-
tagged AMPK2 subunit and an HA-tagged 
R5/PTG protein in mammalian HEK293 
cells. Fig. 1B shows that when myc-
AMPK2 was immunoprecipitated with 
anti-myc antibodies, HA-R5/PTG was also 
recovered in the immunoprecipitates, 
suggesting a physical interaction between 
AMPK2 and R5/PTG. These results were 
confirmed in mouse skeletal muscle crude 
extracts, where we found that endogenous 
AMPK co-immunoprecipitated with 
endogenous R5/PTG when anti-R5/PTG 
antibodies were used in the assay (Fig. 1C). 
 Next, we studied whether as a 
consequence of the interaction between 
AMPK and R5/PTG, this latter protein was 
phosphorylated by the kinase. With this 
aim, we purified from bacteria a protein 
fusion of R5/PTG containing the maltose 
binding protein (MBP) at its N-terminus 
(MBP-R5/PTG). This protein was used in 
in vitro AMPK phosphorylation assays that 
demonstrated that AMPK was able to 
phosphorylate the MBP-R5/PTG fusion 
protein and that the presence of AMP 
(which activates AMPK) in the assay 
improved this phosphorylation (Fig. 1D). 
Control experiments with MBP alone 
showed no efficient phosphorylation by 
AMPK. 
 
2) AMPK modifies the in vivo 
phosphorylation status of R5/PTG. 
 It has been described that R5/PTG 
is a phosphoprotein whose basal level of 
phosphorylation does not change in 
response to insulin (which stimulates the 
Akt/PKB pathway), forskolin (that activates 
the PKA pathway), TPA (12-o-
tetradecanoylphorbol-13-acetate; that 
stimulates the PKC pathway) or epidermal 
growth factor [(27), (28)]. We confirmed 
that R5/PTG was a phosphoprotein by 2D-
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electrophoresis and western blotting of cell 
extracts from CHO cells transfected with 
plasmid pCMV-HA-R5/PTG. As shown in 
Fig. 2A, HA-R5/PTG fusion protein 
produced two major spots. The spot 
migrating faster towards the positive pole 
disappeared upon treatment of the sample 
with -phosphatase, indicating that this spot 
corresponded to phosphorylated forms of 
HA-R5/PTG (Fig. 2A; see arrow). 
Interestingly, if the cells were treated with 
AICAR [an AMPK activator; (29)], we 
obtained a different pattern of spots in the 
2D-E/western blot. The faster migrating 
band disappeared, but a new band of lower 
IEF mobility appeared close to the 
unphosphorylated form (Fig. 2A, right 
panel). Treatment of this sample with -
phosphatase eliminated this intermediate 
form, suggesting that it was also 
phosphorylated (not shown). A similar 
pattern of the spots obtained upon AICAR 
treatment was observed if CHO cells were 
co-transfected with pCMV-HA-R5/PTG 
and a combination of plasmids that 
reconstituted a constitutively active form of 
the AMPK complex (CA-AMPK: 
pcDNA3-AMPK2 T172D, pcDNA3-
AMPK2 and pcDNA3-AMPK1) (Fig. 
2B). These results suggested that the in vivo 
phosphorylation status of R5/PTG varied as 
a result of AMPK activation. 
 We next searched for putative 
AMPK phosphorylation consensus sites in 
the human R5/PTG protein sequence. We 
found that the sequences LKPLKS35CLNI, 
DSKGLS69LTAI and AIHVFS77DLPE 
closely fit with the consensus AMPK site, 
Hyd-(Basic,X)-X-X-Ser/Thr-X-X-X-Hyd, 
where Hyd can be Leu, Met, Ile, Phe or 
Val, and Basic: Arg, Lys or His (30). We 
mutagenized the corresponding Ser residues 
to Ala, but the mutated proteins produced 
the same pattern of in vivo phosphorylation 
(assessed by 2D-E/western) as wild type 
(data not shown), indicating that none of 
these residues were true AMPK 
phosphorylation sites. 
 Then, we decided to identify the 
phosphorylation sites of R5/PTG by mass 
spectrometry. With this aim, we constructed 
a plasmid expressing R5/PTG with an N-
terminal 8xHis tag. This protein fusion was 
purified from CHO cells by Ni+2-affinity 
chromatography and phosphorylated 
residues were identified by mass 
spectrometry (see Materials and Methods). 
In this way, in cells growing under standard 
growth conditions, we identified Ser8 and 
Ser268 as the major phosphorylated 
residues (Fig. 3A). These two residues, 
located at the N- and C-terminal part of the 
protein, respectively, are conserved in 
higher eukaryotes, from fish to human (Fig. 
3B). We repeated the same determination in 
cells growing under conditions of AMPK 
activation by expressing a constitutively 
active form of the AMPK1 (R70Q) 
subunit. In this case, we did not identify 
additional phosphorylation sites, but we 
observed an increase in the extent of the 
phosphorylation of the previously identified 
Ser8 and Ser268 residues (Fig. 3C), 
indicating that these two sites were the 
major targets of AMPK action. Substitution 
of both Ser residues by Ala rendered a 
protein that showed a single spot by 2D-
E/western analysis (similar results were 
obtained in cells growing under conditions 
of AMPK activation; not shown), indicating 
that no more phosphorylated residues were 
present in the double mutant (Fig. 3D). 
 
3) Phosphorylation status of R5/PTG 
does not affect its interaction with 
different partners. 
 We then tested the importance of 
the two phosphorylation sites of R5/PTG on 
the interaction of this glycogen targeting 
subunit with different partners, namely, the 
catalytic subunit of type 1 protein 
phosphatase (PP1c), the AMPK2 and 
AMPK2 subunits of the AMPK complex 
(see above) and laforin, a dual specificity 
protein phosphatase involved in the Lafora 
disease (21). We observed that neither the 
Ser8Ala nor the Ser268Ala mutations 
affected the strength of the interaction 
between the R5/PTG mutated forms and the 
different interaction partners (Fig. 4). 
Similar results were obtained when we 
assayed the Ser8Asp and Ser268Asp 
mutants, mimicking a constitutive negative 
charge in these residues (data not shown), 
indicating that the charge present at 
residues Ser8 and Ser268 did not affect the 
interaction with the assayed partners. 
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4) Phosphorylation status of R5/PTG 
affects its regulation by the laforin/malin 
complex. 
 We and others have recently 
described that the glycogenic activity and 
protein levels of R5/PTG were 
downregulated by the complex formed by 
laforin (a dual specificity protein 
phosphatase) and malin (an E3-ubiquitin 
ligase), two proteins involved in the Lafora 
disease (see Introduction) [(11), (12), (13)]. 
We measured then the glycogenic activity 
of the different mutants under control 
conditions and upon overexpression of the 
laforin/malin complex. In Hek293 cells, we 
observed that the glycogenic activity of the 
wild type form of R5/PTG decreased in 
cells overexpressing the laforin/malin 
complex (Fig. 5A), similar to results 
reported for FTO2B hepatoma cells (12). 
The same result was obtained when the 
R5/PTG S268A mutant was assayed (Fig. 
5A). However, the glycogenic activity of 
the R5/PTG S8A mutant was not affected 
by the overexpression of the laforin/malin 
complex (Fig. 5A). 
 These results could reflect a 
different susceptibility of the mutated forms 
of R5/PTG to be ubiquitinated by the 
laforin-malin complex and then targeted for 
proteasomal degradation. To study if this 
was the case, we analyzed the levels of the 
different R5/PTG forms in cells expressing 
laforin and increasing amounts of malin. As 
observed in Fig. 5B, the levels of wild type 
R5/PTG decreased inversely to the levels of 
malin (a sign of its laforin-malin induced 
degradation). R5/PTG S268A followed the 
same degradation profile as wild type (Fig. 
5B) (similar results were obtained with the 
R5/PTG S268D mutant; not shown). 
However, in the case of R5/PTG S8A, the 
mutated protein was more resistant to the 
action of the laforin-malin complex, 
whereas an R5/PTG S8D mutant 
(mimicking a constitutively negative charge 
in this residue) showed an accelerated 
degradation (Fig. 5B). 
 To confirm these results, we 
examined the rate of R5/PTG degradation 
induced by the laforin-malin complex in the 
presence of cycloheximide (CHX), a 
protein synthesis inhibitor. As shown in 
Fig. 5C, the degradation of R5/PTG was 
prevented in the case of the S8A mutant, 
but accelerated in the case of the S8D 
mutant. These results suggested that 
phosphorylation of R5/PTG by AMPK 
increased its degradation by the laforin-
malin complex. To confirm this hypothesis, 
we treated Hek293 cells with phenformin, a 
known activator of AMPK, and checked the 
rate of R5/PTG degradation induced by the 
laforin-malin complex in the presence of 
cycloheximide (CHX), as above. As shown 
in Fig. 5D, treatment of the cells with 
phenformin increased the degradation rate 
of R5/PTG, indicating that activation of 
AMPK induces the degradation of R5/PTG 
by the laforin-malin complex. 
Supplementary material Fig. S1 shows that 
phenformin treatment activated AMPK and 
this resulted in an increase in the 
phosphorylation of acetyl-CoA carboxylase 
(ACC, a direct substrate of AMPK) and in 
an inactivation of the mTOR pathway, 
reflected by a decrease in the 
phosphorylation of p70-S6 kinase; at the 
same time, endogenous levels of R5/PTG 
were diminished upon long term 
phenformin treatment. 
 As an additional proof of the 
involvement of the laforin-malin complex 
in the degradation of R5/PTG, we depleted 
Hek293 cells of endogenous laforin by 
siRNA silencing. We observed a marked 
increase in the levels of wild type R5/PTG 
in laforin-depleted cells (Fig. 6A), 
confirming the role that the laforin-malin 
complex has in promoting the degradation 
of R5/PTG. We repeated the same 
experiment in cells expressing the R5/PTG 
S8A mutant and observed a higher 
accumulation of this form in comparison to 
wild type, indicating that phosphorylation 
of R5/PTG at Ser8 improves its degradation 
(Fig. 6A). Since our results suggested a 
crucial role for the laforin-malin complex in 
the regulation of the glycogenic activity of 
R5/PTG, we postulated that in patients 
diagnosed with Lafora disease (LD), 
lacking a functional laforin-malin complex, 
the downregulation of R5/PTG would be 
deficient, leading to an accumulation of this 
protein. To test this hypothesis, we 
analyzed, by western blotting, the levels of 
endogenous R5/PTG in extracts from 
primary fibroblasts from LD patients with 
mutations in the laforin gene (epm2a-/-; 
Y86X and R241X nonsense mutations) and 
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from healthy subjects. As shown in Fig. 6B, 
higher levels of endogenous R5/PTG were 
detected in the extracts from LD patients, 
confirming the importance of the laforin-
malin complex in the regulation of R5/PTG. 
 
DISCUSSION 
 Type 1 protein phosphatase (PP1) 
plays a prominent role in the regulation of 
glycogen homeostasis. PP1 is recruited to 
glycogen by a family of glycogen targeting 
subunits that target the phosphatase to its 
glycogenic substrates. As glycogen 
homeostasis is a crucial process, the activity 
of the holoenzyme formed by PP1 and one 
of these glycogenic targeting subunits must 
be tightly regulated. In this work, we 
provide evidence elucidating the molecular 
mechanism by which the activity of one of 
these targeting subunits is regulated. We 
describe that the glycogenic activity of 
R5/PTG is regulated by phosphorylation, 
mediated by the AMP-activated protein 
kinase (AMPK); this kinase phosphorylates 
R5/PTG at two main sites, namely Ser8 and 
Ser268. At first glance, this regulation 
resembles that of GM, another PP1 targeting 
subunit whose activity is downregulated by 
PKA-dependent phosphorylation. However, 
and contrary to the effect produced by the 
phosphorylation of GM, phosphorylation of 
R5/PTG does not interfere with its binding 
to PP1. 
 We and others have recently 
described that the glycogenic activity of 
R5/PTG is downregulated by the laforin-
malin complex, composed of a dual 
specificity protein phosphatase (laforin) and 
E3-ubiquitin ligase (malin) [(11), (12), 
(13)]. Since R5/PTG interacted physically 
with laforin, but not with malin, we also 
suggested that laforin could recognize 
R5/PTG and recruit it to malin, which 
would then ubiquitinate the protein, 
targeting it for proteasomal degradation 
(12). We show in this work that 
phosphorylation of Ser8 by AMPK 
accelerates the laforin-malin-dependent 
degradation of the protein. These results 
add a new role of AMPK in glycogen 
homeostasis, adding to its previously 
known action of phosphorylating and 
inactivating glycogen synthase both in vitro 
and in vivo [(31), (32)]. In addition, these 
results complement our recent report that 
indicates that AMPK enhances the 
interaction between laforin and malin, 
resulting in an improved degradation of 
specific targets (12). In this way, AMPK 
not only improves the formation of a 
functional laforin-malin complex, but also 
makes R5/PTG a better substrate for the 
action of this degradative complex (Fig. 7). 
Since R5/PTG is expressed abundantly in 
adipocytes, skeletal muscle, heart and liver 
(21), the regulatory mechanism described in 
this work could take place in all these 
tissues, which suggests an important role 
for this mechanism in the general 
homeostasis of glycogen. 
 Our results also add to our 
knowledge regarding the importance of the 
laforin-malin complex in glycogen 
biosynthesis. At present, it has been 
described that this complex is involved in 
the degradation of the muscle isoform of 
glycogen synthase (11), the glycogen 
debranching enzyme (AGL) (33), and some 
glycogen targeting subunits of PP1 such as 
R5/PTG [(11), (12), (13)] and R6 (13). 
These results, taken together, suggest a 
crucial role of the laforin-malin complex in 
glycogen biosynthesis. In this work, we 
present evidence that depletion of laforin 
results in an increase in the levels of 
R5/PTG, indicating that this complex is a 
crucial negative regulator of at least this 
glycogen targeting subunit. These results 
are in agreement with the important role 
that these two proteins play in the 
development of the Lafora disease (see 
Introduction). In LD patients lacking a 
functional laforin-malin complex, the 
downregulation of R5/PTG would be 
deficient, leading to a more active R5/PTG-
PP1 phosphatase holoenzyme that would 
stimulate glycogen accumulation. 
Consistent with this interpretation, in 
primary fibroblasts from LD patients with 
mutations in the laforin gene, we have 
observed higher levels of endogenous 
R5/PTG. 
 Recently, an alternative function of 
laforin on glycogen homeostasis has been 
described [(34), (35)]. In this case, laforin 
acts as a phosphatase of complex 
carbohydrates and it has been proposed that 
this function might be necessary for the 
maintenance of normal cellular glycogen. 
Our results are complementary to these 
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observations and, taken together, these 
results define the importance of the laforin-
malin complex in regulating glycogen 
biosynthesis. 
 In conclusion, our work defines a 
novel mechanism for the regulation of 
glycogenic targeting subunits of type 1 
protein phosphatase. In this case, the 
regulation is based on the phosphorylation 
of the regulatory subunit (R5/PTG) by 
AMPK, making it a better substrate for its 
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Fig. 1: AMPK interacts physically with R5/PTG. A) Yeast CTY10.5d cells transformed with 
plasmids pBTM116 (empty), pBTM-AMPK2, pBTM-AMPK2 and pBTM-AMPK1 were 
co-transformed with plasmids pACT2 (empty), pACT2-GM, pACT2-GL and pACT2-R5/PTG. 
Protein interaction was estimated using the yeast two-hybrid system, by measuring the -
galactosidase activity. Values correspond to means from 4-6 different transformants (bars 
indicate standard deviation). B) AMPK2 co-immunoprecipitates with R5/PTG. Protein 
extracts (300 g) were prepared from Hek293 cells transfected with plasmids pCMV-myc-
AMPK2 and pCMV-HA-R5/PTG. One l of anti-myc or pre-immune serum () were used to 
immunoprecipitate the extracts (IP). Pelleted proteins were analyzed by SDS-PAGE and 
immunodetected with anti-HA (upper panel) and anti-myc (lower panel) monoclonal antibodies. 
Proteins in the input crude extracts (CE; 30 g) were also immunodetected with anti-HA and 
anti-myc antibodies. C) Interaction of endogenous R5/PTG and AMPK. Crude extracts (1.5 
mg) from mice skeletal muscle (see materials and Methods) were immunoprecipitated with 1 l 
of anti-R5/PTG antibodies or pre-immune serum (). Immunoprecipitates were analyzed by 
SDS-PAGE and western-blotting using anti-AMPK antibodies. Proteins in the input crude 
extracts (CE, 50 g) were also immunodetected with anti-AMPK and anti-R5/PTG antibodies. 
D) AMPK phosphorylates a MBP-R5/PTG fusion protein in vitro. MBP-R5/PTG (50 ng) and 
MBP (100 ng), produced in bacteria were phosphorylated in vitro using 50 mUnits of AMPK 
(Upstate) and [-32P]ATP, in the presence or absence of 300 M AMP. Samples were analyzed 
by SDS-PAGE and autoradiography. Size standards are indicated in kDa 
 
Fig. 2: AMPK phosphorylates R5/PTG in vivo. A) Cell extracts from CHO cells transfected 
with plasmid pCMV-HA-R5/PTG were analyzed by 2D-electrophoresis and western blotting 
using anti-HA monoclonal antibodies (left panel). An aliquot of these extracts was previously 
treated with -phosphatase (middle panel). Cell extracts from CHO cells treated with AICAR 
(0.5 mM, 6 h) were analyzed similarly (right panel). B) CHO cells were co-transfected with 
plasmid pCMV-HA-R5/PTG and either a combination of plasmids that reconstituted a 
constitutively active form of the AMPK complex (pcDNA3-AMPK2 T172D, pcDNA3-
AMPK2 and pcDNA3-AMPK1; CA-AMPK, right panel) or the same amount of pcDNA3 
empty plasmid (left panel). Cell extracts were obtained and analyzed as in A). 
 
Fig. 3: AMPK induces the phosphorylation of residues Ser8 and Ser268 in R5/PTG. A) 8xHis-
tagged R5/PTG purified from CHO cells was subjected to mass spectrometry analysis. Ions 
corresponding to phosphorylated residues are depicted in bold. B) Sequences corresponding to 
the N- and C-terminus of R5/PTG sequences from different species (Genbank) were aligned 
using the CLUSTAL program. The position of the Ser8 and Ser268 is indicated. C) 8xHis-
tagged R5/PTG was purified from CHO cells grown under conditions of AMPK activation by 
expressing a constitutively active form of AMPK1 (R70Q) subunit. The efficiency of the 
phosphorylation was compared with that obtained in CHO cells grown under standard 
conditions (see Materials and Methods). D) Cell extracts from CHO cells transfected with 
plasmid pCMV-HA-R5/PTG S8A S268A were analyzed by 2D-electrophoresis and western 
blotting using anti-HA monoclonal antibodies. 
 
Fig. 4: Phosphorylation status of R5/PTG does not affect its interaction with different partners. 
Yeast CTY10.5d cells transformed with plasmids pBTM-PP1c, pBTM-AMPK2, pBTM-
AMPK2 and pEG202-Laforin were co-transformed with plasmids pACT2 (empty), pACT2-
R5/PTG wt, pACT2-R5/PTG S8A and pACT2-R5/PTG S268A. Protein interaction was 
estimated using the yeast two-hybrid system, by measuring the -galactosidase activity. Values 
correspond to means from 4-6 different transformants (bars indicate standard deviation). 
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Fig. 5: Phosphorylation status of R5/PTG affects its regulation by the laforin/malin complex. A) 
Hek293 cells were transfected with plasmids expressing the different mutated forms of R5/PTG 
(pCMV-HA-R5/PTG derived plasmids) in combination or not with plasmids pCMV-myc-
Laforin and pcDNA-HA-Malin. Twenty-four hours after the transfection, the amount of 
glycogen was determined as described in Materials and Methods. Bars indicate standard 
deviation of three independent experiments. B) Degradation profiles of the different mutated 
forms of R5/PTG. Hek293 cells were co-transfected with pCMV-HA-R5/PTG derived 
plasmids, pCMV-myc-laforin and different amounts of pcDNA-HA-Malin. Twenty-four hours 
after the transfection, cell extracts (25 g) were analyzed by western blot using anti-HA 
antibodies; anti-actin was used as loading control; a representative analysis is presented. C) 
Degradation profiles of the different mutated forms of R5/PTG in the presence of 
cycloheximide. Hek293 cells were co-transfected with pCMV-myc-laforin, pcDNA3-HA-Malin 
and pCMV-HA-R5/PTG plasmids expressing the indicated proteins. Twenty-four hours after 
the transfection, cycloheximide (CHX, 100 M) was added to the cultures and cell extracts were 
analyzed by western blotting at different times after the addition, using anti-HA and anti-actin 
antibodies (left panel); a representative analysis is presented. The relative intensity of the 
R5/PTG bands respect to the corresponding actin band was plotted as a function of time (right 
panel). D) Degradation profile of R5/PTG in the presence of phenformin. Hek293 cells were co-
transfected with pCMV-myc-laforin, pcDNA3-HA-Malin and pCMV-HA-R5/PTG plasmids as 
in B). Twenty-four hours after the transfection, cells were treated with 5 mM phenformin for 2 h 
and then cycloheximide (CHX, 100 M) was added to the cultures. Cell extracts were analyzed 
by western blotting at different times after the addition, using anti-HA and anti-actin antibodies 
(left panel); a representative analysis is presented. The relative intensity of the R5/PTG bands 
respect to the corresponding actin band was plotted as a function of time (right panel). 
 
Fig. 6: Depletion of laforin increases the levels of R5/PTG. A) Hek293 cells were co-
transfected with plasmids pCMV-HA-R5/PTG (WT and S8A) and with 1 g of pSUPER-laf 
plasmid expressing laforin siRNA (see Materials and Methods) or with an empty vector (c-). 
Twenty-four hours after the transfection, cells extracts (25 g) were analyzed by western 
blotting using anti-HA, anti-laforin and anti-actin antibodies (right panel). A longer exposure of 
the blot with anti-HA was used to assess the levels of the proteins in the absence of laforin 
silencing; a representative analysis is presented. The relative intensity of the R5/PTG bands 
under control and laforin-depletion conditions in three independent experiments was plotted 
(left panel); bars indicate standard deviation. B) Cell extracts from primary fibroblasts from two 
LD patients with mutations in the laforin gene (epm2a-/-; Y86X and R241X) and from two 
healthy subjects (#1 and #2) were analyzed by western blotting using anti-R5/PTG and anti-
laforin and anti-tubulin antibodies (right panel); a representative analysis is presented. The 
relative intensity of the R5/PTG bands with respect to the corresponding tubulin bands, in three 
independent experiments, was plotted (left panel); bars indicate standard deviation. 
Fig. 7: Proposed role of AMPK on glycogen biosynthesis. See text for details. PP1c: catalytic 
subunit of type 1 protein phosphatase; GS: glycogen synthase; Ph: glycogen phosphorylase. 
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